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SUMMARY
Background—Given recent concerns of efavirenz reducing the efficacy of contraceptive 
implants, we sought to determine if pregnancy rates differ among HIV-positive women using 
various contraceptive methods and efavirenz- or nevirapine-based antiretroviral therapy (ART) 
regimens.
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Methods—We conducted a retrospective cohort analysis of HIV-positive women aged 15–45 
years enrolled in HIV care facilities in western Kenya from January 2011 to December 2013. 
Pregnancy was diagnosed clinically and the primary exposure was a combination of contraceptive 
method and ART regimen. We used Poisson models, adjusting for repeated measures, as well as 
demographic, behavioral and clinical factors, to compare pregnancy rates among women on 
different contraceptive/ART combinations.
Findings—24,560 women contributed 37,635 years of follow-up with 3,337 incident 
pregnancies. Among women using implants, adjusted pregnancy incidence for nevirapine- and 
efavirenz-based ART users were 1·1 (95% CI 0·72–1·5) and 3·3 (95% CI 1·8–4·8) per 100 women-
years (w-y), respectively (adjusted incidence rate ratio (aIRR) 3·0, 95% CI 1·3–4·6). Among 
women using depomedroxyprogesterone acetate (DMPA), adjusted pregnancy incidence for 
nevirapine- and efavirenz-based ART users were 4·5 (95% CI 3·7–5·2) and 5·4 (95% CI 4·0–6·8) 
per 100 w-y, respectively (aIRR 1·2, 95% CI 0·91–1·5). Women using other contraceptive 
methods, except for intrauterine devices and permanent methods, experienced 3·1–4·1 higher rates 
of pregnancy than women using implants, with 1·6–2·8 higher rates specifically among women 
using efavirenz-based ART.
Interpretation—While HIV-positive women using implants on efavirenz-based ART faced three 
times higher risk of contraceptive failure than those on nevirapine-based ART, these women still 
experienced lower contraceptive failure rates than women on all other contraceptive methods, 
except for intrauterine devices and permanent methods. Guidelines for contraceptive and ART 
combinations should balance the failure rates for each contraceptive method and ART regimen 
combination against the high effectiveness of implants.
Funding—Supported by the President’s Emergency Plan for AIDS Relief and the Centers for 
Disease Control and Prevention.
INTRODUCTION
Unintended pregnancies among HIV-positive women may have significant consequences for 
HIV-related maternal morbidity1 and vertical transmission of HIV.2 Effective contraception 
can prevent unintended pregnancies, but potential interactions between antiretroviral therapy 
(ART) and hormonal contraception, particularly between efavirenz-based ART and 
subdermal implants, may compromise a contraceptive’s efficacy. This issue is particularly 
important to the nearly 13 million women living with HIV in sub-Saharan Africa.3 First, 
there is increasing use of efavirenz-based ART as the first-line regimen, facilitated by its 
availability as a fixed dose combination pill.4 Second, there is increasing access over time to 
hormonal contraceptives for family planning in sub-Saharan Africa, including implants, 
which are used by up to 14% of HIV-positive women in the region.5–7 Implants prevent 
pregnancies by gradually releasing synthetic forms of progesterone, etonogestrel or 
levonorgestrel, into the serum, thereby suppressing ovulation, increasing cervical mucus 
viscosity, and altering the endometrium. The two types of implants commonly used in sub-
Saharan Africa are Implanon® (68 mg etonogestrel/rod) and Jadelle® or Sino Implant (II)® 
(75 mg levonorgestrel/rod x 2 rods). The contraceptive failure rate with implants is reported 
below 1%,8,9 making them the most effective reversible contraceptive method available.
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Because of pharmacokinetic data regarding potential drug-drug interactions between ART 
and certain hormonal contraceptives, current national guidelines often advise dual use of 
condoms or alternative contraceptive methods.10–12 Hormonal contraceptives, including 
etonogestrel and levonorgestrel, are metabolized by hepatic cytochrome P450 (CYP450) 
enzymes, specifically by CYP3A4.13 Antiretrovirals, including protease inhibitors, non-
nucleoside reverse transcriptase inhibitors (NNRTIs), such as nevirapine and efavirenz, and 
cobicistat-boosted agents, influence the activity of CYP3A4 and 2B6 enzymes; NNRTIs are 
specifically implicated in CYP3A4 induction.13 Recently, two pharmacokinetic studies 
found reduced etonogestrel or levonorgestrel concentrations in women on implants and 
efavirenz-based ART.14,15
The ultimate significance of any drug-drug interaction remains unclear as few studies have 
examined contraceptive failure rates with efavirenz and implant use. Some case reports,16–19 
two retrospective studies,20,21 and a pharmacokinetic study from Uganda22 document 
contraceptive failures among women using efavirenz-based ART and implants, though 
another study from Brazil found no pregnancies among its implant and ART users.23 In light 
of the limited existing literature and on-going debate regarding implant use among women 
on efavirenz-based ART, we sought to determine if pregnancy rates differ among HIV-
positive women enrolled in care in Kenya using various combinations of contraceptive 
methods and ART regimens. We hypothesized that there would not be a significant 
difference in the pregnancy rates among women using implants and nevirapine- vs. 
efavirenz-based ART.
METHODS
Overview of study design, site and population
We conducted a retrospective, longitudinal cohort analysis of 24,560 HIV-positive women 
from 15 to 45 years of age enrolled at HIV health facilities in Kisumu, Homabay, and 
Migori counties in western Kenya supported by Family AIDS Care & Education Services 
(FACES). FACES is a President’s Emergency Plan for AIDS Relief-sponsored program 
jointly managed by the University of California San Francisco (UCSF) and the Kenya 
Medical Research Institute (KEMRI).24 See supplemental text for additional background 
information on the services FACES provides. The Committee on Human Research at UCSF, 
the Ethical Review Committee at KEMRI, and the U.S. Centers for Disease Control and 
Prevention approved the use of de-identified patient information for research purposes.
Participant information was extracted from the FACES electronic medical record system, 
OpenMRS, from clinical visits from all women HIV-positive aged 15–45 years dating 
between January 1, 2011 and December 31, 2013 from the 19 FACES-supported HIV health 
facilities with OpenMRS. No exclusion criteria were applied. These facilities follow the 
Kenya Ministry of Health guidelines for frequency of visits, which is generally every 1–3 
months for patients on ART and every 6 months for those not on ART.25 Women 
contributed observation time starting with a visit after January 1, 2011 until their last 
documented visit or end of the study period. An observation in the cohort was defined by a 
change in exposure categories; therefore, more than one clinical visit may have contributed 
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data to the same observation. See supplemental text for additional information on data 
collection and quality control measures utilized by FACES.
Definitions of variables
Primary Exposures—Contraceptive method was documented at each clinic visit and then 
categorized as: 1) implants, which included information on specific types, such as 
Implanon® or Jadelle®; 2) depomedroxyprogesterone acetate (DMPA); 3) combined oral 
contraceptives (COCs) or oral contraceptive pills (OCPs); 4) other more effective 
contraceptive methods (MEC; intrauterine devices (IUDs) and permanent methods); 5) less 
effective contraceptive methods (LEC; male and female condoms and “natural” 
contraceptive methods, such as withdrawal and rhythm); or 6) no contraceptive method. 
When multiple methods were documented at the same visit, the contraceptive method was 
assigned according to the following hierarchy: MEC over implants over DMPA over COCs 
or OCPs over LEC.
ART regimen was documented at each clinic visit and then categorized as: 1) efavirenz-
based ART; 2) nevirapine-based ART; 3) lopinavir/ritonavir-based ART; or 4) no ART. We 
defined an “ART regimen” as at least a three-drug combination of antiretrovirals; women 
exposed to single-dose nevirapine or zidovudine monotherapy for prevention of mother-to-
child transmission were categorized as being on “no ART.”
Since we were interested in the interaction of contraceptive method and ART regimen on 
pregnancy rates, we captured exposure based on a combination of one of six contraceptive 
and four ART categories, resulting in 24 total combination categories. This categorization 
could be time-dependent, with women switching categories when they changed 
contraceptive method, ART regimen, or both. Duration on a combined category was 
calculated in days from the earliest record until the participant switched a category, became 
pregnant, or was censored at her last visit during the study period. If missing, contraceptive 
method and ART regimen were imputed from the most recent previous documented record. 
Of note, implant removal dates were not recorded in OpenMRS so when a participant was 
recorded to be on a different contraceptive method, except for condoms, we assumed 
implant discontinuation.
Outcome—Our primary outcome was incident pregnancy diagnosed clinically, through 
self-reports or presenting while gravid; biochemical tests are not routinely used to confirm 
clinically suspected pregnancies in this setting. We estimated the date of incident pregnancy 
as the date of likely conception based on reports of last menstrual period or estimated 
delivery date. For 303 of 3337 (9.1%) pregnancies we could not determine the date of likely 
conception based on these two criteria. For these observations, we used the median time of 
documented clinical pregnancy to the date of likely conception derived from the remainder 
of the cohort (4·2 months) and imputed this value for those missing the date of likely 
conception. We tracked reported pregnancies until nine months after the end of our 
observation period, to capture pregnancies that may have occurred within our study period.
Women were censored: 1) for the duration of a full-term pregnancy (38 weeks) plus the 
subsequent 12 weeks for lactational amenorrhea (50 weeks total), after which they were able 
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to re-enter the cohort; or 2) at last visit during the study period. We allowed for multiple 
pregnancies to occur. For 8,847 of 94,162 (9.4%) observations that were missing pregnancy 
status, we assumed these women were not pregnant.
Covariates—Based on previously identified factors associated with the exposures, 
outcome, or both,26–28 we considered the following covariates for inclusion in the 
multivariable models: baseline age, educational attainment, marital status, number of living 
children, HIV-positive status disclosure to partner, and time-dependent percent use of 
condoms, body mass index (BMI), World Health Organization (WHO) stage of HIV disease, 
CD4 cell count, self-reported ART adherence, and use of anti-tuberculosis medications 
during the observation period (see supplemental text for definitions of each covariate).
Statistical analysis
Frequencies and proportions are presented for categorical variables, mean and standard 
deviation (SD) for normally distributed variables, and median and interquartile range (IQR) 
for non-normally distributed continuous variables. We used multiple imputation by iterative 
chained equations to account for missing information. We used unadjusted and adjusted 
Poisson models with robust standard errors to estimate incident pregnancy rates per 100 
woman-years (w-y) for each exposure combination category. Adjusted incident rates and 
rate ratios (aIRR) are conditional and evaluated at the mean of all the covariates. We 
selected covariates on a priori grounds and included them in the final model regardless of 
the p-values in the bivariate analysis; however, due to lack of variation, self-reported ART 
adherence was excluded from the final model. To reduce skewness, we used log10 and 
square root transformations of BMI and CD4 cell count, respectively. To better meet the 
assumptions of linearity in our adjusted models, we added quadratic terms of all continuous 
variables.
We conducted three sensitivity analyses on the original dataset by placing more stringent 
criteria on both the definitions of contraceptive and ART exposure and pregnancy. If a 
woman was recorded being on a long-acting contraceptive method (implants, IUDs, or 
permanent methods), followed by another contraceptive method or no method for one 
observation, and then back on the prior long-acting contraceptive method, we considered the 
recording of the intermediate contraceptive method an error and replaced it with the first 
contraceptive method. If a woman was noted to switch from another contraceptive method 
or no method to a long-acting contraceptive method, we required two consecutive visits 
documenting its use to consider it a true switch. Similarly, if another ART regimen was 
“sandwiched” between two identical ART regimens, we considered it an error and replaced 
it with the first ART regimen. Pregnancies were verified through the use of two data points, 
either through two visit dates recording a pregnancy or one visit date where both a 
pregnancy as well as an estimated delivery date were noted. Finally, we conducted a fourth 
sensitivity analysis by dropping the 8,847 of 94,162 (9.4%) observations missing pregnancy 
status. Data were prepared using SAS version 9·3 (Cary, North Carolina, USA) and analyses 
were conducted using STATA version 12·1 (College Station, Texas, USA).
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Role of funding source
The funders had no involvement in the study design, data collection and analysis, 
interpretation of results, and writing or publication of this report other than obtaining 
clearance from the Centers for Disease Control and Prevention-Kenya officials prior to 
manuscript submission.
RESULTS
General characteristics of overall cohort
24,560 women contributed 94,162 observations to the analysis, representing 37,635 w-y of 
observation. The women contributed a median of 11 (IQR 5–17) visits, 3 (IQR 2–5) 
observations, and 18 (IQR 5–30) months of person-time during the study period. Women 
had a median age of 31 (IQR 26–36) years, 18% had completed primary schooling or a 
higher level of education, 44% were married or co-habiting, and participants had a median 
of two living children (IQR 1–3). The mean participant BMI was 22 kg/m2 (SD ±4), 66% of 
the women were in WHO clinical stages 1 or 2, and 44% had CD4 counts ≥500 cells/mm3 
proximal to the start of the observation period (table 1).
In this cohort, implants were used in 6,232 (6·6%), DMPA in 16,363 (17·4%), COC/OCPs in 
2,495 (2·7%), other more effective contraception in 2,811 (3·0%), less effective 
contraception in 34,444 (36·6%), and no contraceptive method in 30,934 (32·9%) of the 
observations. Nevirapine-based ART was used in 46,132 (49·0%), efavirenz-based ART in 
13,573 (14·4%), lopinavir/ritonavir-based ART in 3,649 (3·9%), and no ART in 30,494 
(32·4%) of the observations (table 1 and supplemental table 1).
Pregnancy incidence
Overall, 3,337 incident pregnancies occurred, including 157 multiple pregnancies, resulting 
in a pregnancy rate of 8·9 per 100 w-y (95% CI 8·6–9·2). Among implant users, adjusted 
pregnancy incidence was 1·4 (95% CI 1·1–1·8) per 100 w-y. Stratified by ART regimen, 
adjusted rates for nevirapine- and efavirenz-based ART users were 1·1 (95% CI 0·72–1·5) 
and 3·3 (95% CI 1·8–4·8) per 100 w-y, respectively (aIRR 3·0, 95% CI 1·3–4·6; table 2).
Adjusted pregnancy incidence for etonogestrel and levonorgestrel implant users were 1·4 
(95% CI 1·0–1·8) and 1·4 (95% CI 0·82–2·0) per 100 w-y, respectively. Among etonogestrel 
implant users, pregnancy incidence for nevirapine- and efavirenz-based ART users were 1·2 
(95% CI 0·67–1·6) and 3·0 (95% CI 1·4–4·7) per 100 w-y, respectively (aIRR 2·6, 95% CI 
0·89–4·3). Among levonorgestrel implant users, pregnancy incidence for nevirapine- and 
efavirenz-based ART users were 1·0 (95% CI 0·38–1·7) and 4·2 (95% CI 0·84–7·5) per 100 
w-y, respectively (aIRR 4·1, 95% CI 0–8·2; supplemental table 2).
Among the overall cohort, adjusted pregnancy rates for women on all other contraceptive 
methods, except for IUDs and permanent methods, were 3·1–4·1 times higher than with 
implants. Among efavirenz-based ART users, adjusted pregnancy rates on all other 
contraceptive methods, except for IUDs and permanent methods, were 1·6–2·8 times higher 
than with implants (tables 2 and 3). For example, among DMPA users, pregnancy rates for 
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those on nevirapine- and efavirenz-based ART were 4·5 (95% CI 3·7–5·2) and 5·4 (95% CI 
4·0–6·8) per 100 w-y, respectively, and among COC/OCPs users, pregnancy rates for 
women on nevirapine- and efavirenz-based ART were 5·8 (95% CI 4·0–7·6) and 9·3 (95% 
CI 4·6–14·0) per 100 w-y, respectively (table 2). However, among IUD and permanent 
methods users, pregnancy rates for those on nevirapine- and efavirenz-based ART were 0·92 
(95% CI 0·28–1·6) and 0·93 (0–2·2) per 100 w-y. Supplemental table 3 contains the 
unadjusted and adjusted pregnancy rates ratios for the covariates. The sensitivity analyses 
did not significantly alter our original adjusted rate ratios for incident pregnancy 
(supplemental tables 4–7).
DISCUSSION
In the largest study to date to examine incident pregnancies in nearly 25,000 HIV-positive 
women from western Kenya using various combinations of contraceptive methods and ART, 
we found that among women using either etonogestrel or levnorgestrel implants, adjusted 
pregnancy rates were three times higher among those on efavirenz- versus nevirapine-based 
ART. However, implant use was associated with substantially lower pregnancy rates than 
use of alternative contraceptive methods other than IUDs and permanent methods, even 
among women on efavirenz-based ART.
Implants are among the most effective forms of contraception available,29 and the most 
readily available, reversible, and effective form of contraception in western Kenya. Due to 
the implant’s high effectiveness, despite likely drug-drug interactions reducing its efficacy 
in women on efavirenz, women using implants and efavirenz-based ART still experienced 
lower pregnancy rates than women on other readily-available contraceptives in our study. 
For example, among women using efavirenz-based ART, those reporting use of DMPA had 
1·6 times higher incident pregnancies compared to those using implants. Contraceptive 
failure with DMPA is more common than with implants since proper DMPA use requires 
repeat injections on a timely basis, and, therefore, DMPA is more user dependent than 
maintaining a subdermal implant. As such, some women and their providers are likely to 
still choose implants for contraception while on efavirenz-based ART. HIV programs and 
providers need to actively engage women in conversations regarding potential risks and 
benefits of each contraceptive method, as greater choice exists with options for 
contraceptives than ART regimens in resource-limited settings. Counseling and messaging 
around implant and efavirenz use needs to be comprehensive and include effectiveness data 
regarding implants compared to other contraceptive methods. Certainly, further research on 
strategies to optimize the implant’s efficacy, such as shortening the duration of the implant 
use, is urgently needed. However, until additional effective contraceptive or ART 
alternatives are widely available to HIV-positive women, we caution against policies 
excluding implants as a choice for women using efavirenz-based ART.
Few contraceptives as efficacious as implants exist in resource-limited settings for women 
prescribed efavirenz-based ART, the currently recommended first-line therapy in sub-
Saharan Africa.4 Our data show that, even among women using efavirenz-based ART, those 
using other hormonal contraceptives face up to three times higher pregnancy rates than 
women using implants. Permanent methods are not viable options for women desiring 
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reversible contraception. Though IUDs, particularly non-hormonal IUDs, are a compelling 
long-acting reversible alternative to implants, they are seldom used in sub-Saharan Africa, 
for reasons that include patient and provider preferences and misconceptions30 and lack of 
provider training, sufficient space, or privacy for insertion. In settings such as western 
Kenya, DMPA is the leading alternative to implants for more effective contraception, which 
requires the user to return every three months for repeat injections. Given this high level of 
user action requirement, HIV-positive women on DMPA may face higher risks of non-
compliance and, hence, incident pregnancies. Oral contraceptives need to be taken daily, are 
therefore limited by adherence issues, and may be liable to similar drug-drug interactions as 
implants and efavirenz.13
Efavirenz-based ART is not only the WHO recommended first-line therapy for resource-
limited countries, it is also the first single-pill combination available in these settings, which 
has marked advantages in facilitating adherence.31 Nevirapine-based ART has a less 
favorable side effect and resistance profile and has more limited virological efficacy than 
efavirenz.32,33 We observed lower incident pregnancies among women on implants in the 
lopinavir/ritonavir- vs. efavirenz-based ART or no ART groups, a finding that appears 
consistent with a pharmacokinetic study where etonogestrel concentrations among implant 
users were higher in women using lopinavir/ritonavir-based ART vs. no ART.14 However, 
with too few women contributing person-time to the lopinavir/ritonavir-based ART 
categories in our analysis, we cannot draw strong conclusions. Lopinavir/ritonavir-based 
ART is also a less attractive alternative than newer generation protease inhibitors due to its 
side effect profile, virological efficacy, and pill burden.34,35 Atazanavir/ritonavir-based ART 
is now approved as second line therapy in some resource-limited settings such as Kenya,36 
and may be a better alternative to efavirenz-based ART for women wishing to use implants. 
Integrase-inhibitors, such as raltegravir, are becoming available in the private sector in 
resource-limited settings and may be viable alternatives as well. However, further clinical 
and pharmacokinetic studies need to evaluate these newer ART regimens in combination 
with implants.
Although our study’s sample size is large and we followed women for up to three years, our 
study has several limitations. First, we were limited in our accounting of contraceptive use 
to the electronic records available from clinic visits, where it is possible that clinicians did 
not accurately document contraceptive initiation, continuation, or discontinuation. Second, 
since we were unable to determine contraceptive initiation dates, we could not ensure that 
the pregnancies fell within the efficacy periods of each contraceptive method nor determine 
at which point in the life of the implant women became pregnant. Third, the rates of 
pregnancy with more effective contraceptive methods in our study are slightly higher than 
those published in the literature,29 though our overall incident pregnancy rate of 8.9 
pregnancies per 100 w-y is within the range of rates reported previously among women with 
or at high risk for HIV.37–39 Some women may have falsely reported using a contraceptive 
method given the social desirability of using contraception and difficulties in discussing 
fertility intentions with providers.40 This difference may also be due to data quality issues 
with programmatic data, such as misclassification of contraceptive methods or pregnancies 
due to data entry errors; however, our sensitivity analyses, attempting to correct for data 
entry errors, did not uncover differential biases by contraceptive method or ART regimen. 
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Fourth, we do not know pregnancy intention, though one can safely assume that women 
using long-acting contraception intend to avoid pregnancy. Fifth, we were not able to 
account for certain covariates, such as measures of sexual activity or ART adherence.
In conclusion, our study supports the growing evidence that efavirenz-based ART may 
reduce the effectiveness of contraceptive implants, though implants continue to remain one 
of the most effective forms of reversible contraception, even in combination with efavirenz-
based ART. As such, we advocate for offering HIV-positive women all currently available 
contraceptive methods, including implants, and counseling them on the failure rates when 
used in combination with efavirenz-based ART. More prospective and pharmacokinetic 
studies, which better account for contraceptive and ART adherence and pregnancy 
ascertainment, are urgently needed to further explore the interactions between hormonal 
contraceptives and ART and guide the use and availability of newer single-pill combination 
ART regimens that are effective, well tolerated, and do not reduce contraceptive 
effectiveness.
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Acknowledgments
We especially thank the FACES data team, including the data clerks. We gratefully acknowledge the Director of 
KEMRI, the Director of KEMRI’s Centre for Microbiology, and the Nyanza Provincial Ministries of Health for 
their support in conducting this research. This publication was made possible by support from the U.S. President’s 
Emergency Plan for AIDS Relief (PEPFAR) through a cooperative agreement from the U.S. Centers for Disease 
Control and Prevention (CDC), Division of Global HIV/AIDS (PS001913). Dr. Patel was supported by the U.S. 
National Institutes of Health Biology of Infectious Diseases Training Program (T32AI007641) and Dr. Newmann 
by the National Center for Advancing Translational Sciences through the UCSF-CTSI (KL2TR000143). The 
findings and conclusions in this paper are those of the authors and do not necessarily represent the official position 
of the U.S. Centers for Disease Control and Prevention or the Government of Kenya.
References Cited
1. Calvert C, Ronsmans C. HIV and the risk of direct obstetric complications: a systematic review and 
meta-analysis. PLoS One. 2013; 8:e74848. [PubMed: 24124458] 
2. Halperin DT, Stover J, Reynolds HW. Benefits and costs of expanding access to family planning 
programs to women living with HIV. AIDS. 2009; 23(Suppl 1):S123–30. [PubMed: 20081384] 
3. Joint United Nations Programme on HIV/AIDS (UNAIDS). Global report: UNAIDS report on the 
global AIDS epidemic 2013. Geneva, Switzerland: 2013. http://scholar.google.com/scholar?
hl=en&btnG=Search&q=intitle:Global+report:+UNAIDS+report+on+the+global+AIDS+epidemic
+2013#0 [accessed 2 Jun 2014]
4. World Health Organization. Consolidated guidelines on the use of anti-retroviral drugs for treating 
and preventing HIV infection: recommendations for a publich health approach. Geneva, 
Switzerland: 2013. http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf
5. Grossman D, Onono M, Newmann SJ, et al. Integration of family planning services into HIV care 
and treatment in Kenya: A cluster-randomized trial. AIDS. 2013; 27:S77–85. [PubMed: 24088687] 
6. Wall KM, Vwalika B, Haddad L, et al. Impact of long-term contraceptive promotion on incident 
pregnancy: a randomized controlled trial among HIV-positive couples in Lusaka, Zambia. J Acquir 
Immune Defic Syndr. 2013; 63:86–95. [PubMed: 23202814] 
PATEL et al. Page 9













7. Khu NH, Vwalika B, Karita E, et al. Fertility goal-based counseling increases contraceptive implant 
and IUD use in HIV-discordant couples in Rwanda and Zambia. Contraception. 2013; 88:74–82. 
[PubMed: 23153896] 
8. Graesslin O, Korver T. The contraceptive efficacy of Implanon: a review of clinical trials and 
marketing experience. Eur J Contracept Reprod Health Care. 2008; 13(Suppl 1):4–12. [PubMed: 
18330813] 
9. Steiner MJ, Lopez LM, Grimes Da, et al. Sino-implant (II)--a levonorgestrel-releasing two-rod 
implant: systematic review of the randomized controlled trials. Contraception. 2010; 81:197–201. 
[PubMed: 20159174] 
10. Malawi Ministry of Health. Clinical management of HIV in children and adults: Malawi integrated 
guidelines for providing HIV services. Lilongwe, Malawi: 2014. http://cms.medcol.mw/
cms_uploaded_resources/18381_16.pdf
11. Panel on Antiretroviral Guidelines for Adults and Adolescents. Department of Health and Human 
Services. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. 
Ministry of Health; Kenya: 2014. http://aidsinfo.nih.gov/contentfiles/lvguidelines/
adultandadolescentgl.pdf
12. Department of Health (Republic of South Africa). Circular: Changes in the prescription of 
progestin subdermal implants (Implanon) in women who are taking enzyme inducing drugs such 
as efavirenz for HIV, rifampicin for TB, and certain drugs used for epilepsy (carbamazepine, 
phenytoin, and phenobarbital). http://www.sahivsoc.org/upload/documents/Circular-
ChangesinthePrescriptionofProgestinSubdermalImplants.pdf
13. Tseng A, Hills-Nieminen C. Drug interactions between antiretrovirals and hormonal 
contraceptives. Expert Opin Drug Metab Toxicol. 2013; 9:559–72. [PubMed: 23425052] 
14. Vieira CS, Bahamondes MV, de Souza RM, et al. Effect of antiretroviral therapy including 
lopinavir/ritonavir or efavirenz on etonogestrel-releasing implant pharmacokinetics in HIV-
positive women. J Acquir Immune Defic Syndr. 2014; 66:378–85. [PubMed: 24798768] 
15. Scarsi K, Lamorde M, Darin K, et al. Efavirenz- but not nevirapine-based antiretroviral therapy 
decreases exposure to the levonorgestrel released from a sub-dermal contraceptive implant. J Int 
AIDS Soc. 2014; 17:19484. [PubMed: 25393993] 
16. Matiluko AA, Soundararjan L, Hogston P. Early contraceptive failure of Implanon in an HIV-
seropositive patient on triple antiretroviral therapy with zidovudine, lamivudine and efavirenz. J 
Fam Plann Reprod Health Care. 2007; 33:277–8. [PubMed: 17925115] 
17. McCarty EJ, Keane H, Quinn K, Quah S. Implanon® failure in an HIV-positive woman on 
antiretroviral therapy resulting in two ectopic pregnancies. Int J STD AIDS. 2011; 22:413–4. 
[PubMed: 21729965] 
18. Leticee N, Viard J-P, Yamgnane A, Karmochkine M, Benachi A. Contraceptive failure of 
etonogestrel implant in patients treated with antiretrovirals including efavirenz. Contraception. 
2012; 85:425–7. [PubMed: 22036046] 
19. Lakhi N, Govind A. Implanon failure in patients on antiretroviral medication: the importance of 
disclosure. J Fam Plann Reprod Health Care. 2010; 36:181–2. [PubMed: 20659385] 
20. Perry SH, Swamy P, Preidis G, Mwanyumba A, Motsa N, Sarero HN. Implementing the Jadelle 
implant for women living with HIV in a resource-limited setting in sub-Saharan Africa: concerns 
for drug interactions leading to unintended pregnancies. AIDS. 2014; 28:4–6.
21. Pyra, M.; Heffron, R.; Mugo, NR., et al. Effectiveness of contraception for HIV-infected women 
using antiretroviral therapy: combined data from 3 longitudinal studies. 8th IAS Conference on 
HIV Pathogenesis, Prevention, and Treatment; Vancouver, Canda. 19–22 July, 2015; http://
pag.ias2015.org/Search/Index
22. Scarsi, K.; Nakalema, S.; Byakika-Kibwika, P., et al. Levonorgestrel Implant + EFV-Based ART: 
Unintended Pregnancies and Associated PK Data. Conference on Retroviruses and Opportunistic 
Infections (CROI); Seattle, Washington. 2015; p. Abstract number: 85LB
23. Kreitchmann R, Innocente AP, Preussler GMI. Safety and efficacy of contraceptive implants for 
HIV-infected women in Porto Alegre, Brazil. Int J Gynecol Obstet. 2012; 117:81–2.
24. Lewis-Kulzer J, Penner Ja, Marima R, et al. Family model of HIV care and treatment: A 
retrospective study in Kenya. J Int AIDS Soc. 2012; 15:8. [PubMed: 22353553] 
PATEL et al. Page 10













25. National AIDS/STI Control Program (NASCOP) Kenya. Guidelines for antiretroviral therapy in 
Kenya. 4. Nairobi, Kenya: 2011. http://healthservices.uonbi.ac.ke/sites/default/files/centraladmin/
healthservices/KenyaTreatmentGuidelines2011.pdf
26. Kaida A, Matthews LT, Kanters S, et al. Incidence and predictors of pregnancy among a cohort of 
HIV-positive women initiating antiretroviral therapy in Mbarara, Uganda. PLoS One. 2013; 
8:e63411. [PubMed: 23704906] 
27. Schwartz SR, Rees H, Mehta S, Venter WDF, Taha TE, Black V. High incidence of unplanned 
pregnancy after antiretroviral therapy initiation: findings from a prospective cohort study in South 
Africa. PLoS One. 2012; 7:e36039. [PubMed: 22558319] 
28. Homsy J, Bunnell R, Moore D, et al. Reproductive intentions and outcomes among women on 
antiretroviral therapy in rural Uganda: a prospective cohort study. PLoS One. 2009; 4:e4149. 
[PubMed: 19129911] 
29. Trussell, J. Contraceptive efficacy. In: Hatcher, R.; Trussell, J.; Nelson, A.; Cates, W.; Kowal, D.; 
Policar, M., editors. Contraceptive Technology. 20. New York: Ardent Media; 2011. 
30. Bryant AG, Kamanga G, Stuart GS, Haddad LB, Meguid T, Mhango C. Immediate postpartum 
versus 6-week postpartum intrauterine device insertion: a feasibility study of a randomized 
controlled trial. Afr J Reprod Health. 2013; 17:72–9. [PubMed: 24069753] 
31. Gandhi M, Gandhi RT. Single-Pill Combination Regimens for Treatment of HIV-1 Infection. N 
Engl J Med. 2014; 371:248–59. [PubMed: 25014689] 
32. Pillay P, Ford N, Shubber Z, Ferrand Ra. Outcomes for Efavirenz versus Nevirapine-Containing 
Regimens for Treatment of HIV-1 Infection: A Systematic Review and Meta-Analysis. PLoS One. 
2013; 810.1371/journal.pone.0068995
33. Bannister WP, Ruiz L, Cozzi-Lepri A, et al. Comparison of genotypic resistance profiles and 
virological response between patients starting nevirapine and efavirenz in EuroSIDA. AIDS. 2008; 
22:367–76. [PubMed: 18195563] 
34. Molina J-M, Andrade-Villanueva J, Echevarria J, et al. Once-Daily Atazanavir / Ritonavir 
Compared With Twice-Daily Lopinavir / Ritonavir, Each in Combination With Tenofovir and 
Emtricitabine, for Management of Antiretroviral-Naive HIV-1 Infected Patients : 96-Week 
Efficacy and Safety Results of the CASTLE. J Acquir Immune Defic Syndr. 2010; 53:323–32. 
[PubMed: 20032785] 
35. Orkin C, Dejesus E, Khanlou H, et al. Final 192-week efficacy and safety of once-daily darunavir/
ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the 
ARTEMIS trial. HIV Med. 2013; 14:49–59. [PubMed: 23088336] 
36. National AIDS/STI Control Program (NASCOP) Kenya. Guidelines on use of antiretroviral drugs 
for treating and preventing HIV infection: Rapid Advice June 2014. Ministry of Health; Kenya: 
2014. http://healthservices.uonbi.ac.ke/sites/default/files/centraladmin/healthservices/Rapid
%20Advice%20Booklet%202014%2024%20June%2012%20noon_0.pdf
37. Blanchard K, Bostrom A, Montgomery E, et al. Contraception use and effectiveness among 
women in a trial of the diaphragm for HIV prevention. Contraception. 2011; 83:556–63. [PubMed: 
21570554] 
38. Sibeko S, Baxter C, Yende N, Karim QA, Karim SSA. Contraceptive Choices, Pregnancy Rates, 
and Outcomes in a Microbicide Trial. Obstet Gynecol. 2011; 118:895–904. [PubMed: 21934454] 
39. Mugo NR, Hong T, Celum C, et al. Pregnancy incidence and outcomes among women receiving 
preexposure prophylaxis for HIV prevention: a randomized clinical trial. JAMA. 2014; 312:362–
71. [PubMed: 25038355] 
40. Wagner G, Linnemayr S, Kityo C, Mugyenyi P. Factors associated with intention to conceive and 
its communication to providers among HIV clients in Uganda. Matern Child Health J. 2012; 
16:510–8. [PubMed: 21359828] 
PATEL et al. Page 11













Panel: Research in context
Evidence before this study
We searched PubMed for articles published in English between January 1, 1950 and 
August 18, 2015 with a combination of the following terms: “efavirenz”, 
“antiretrovirals”, “antiretroviral therapy”, “contraceptive implants”, “implants”, and 
“contraceptive failure.” We also included pertinent published abstracts from leading HIV 
conferences. We found four case reports, two pharmacokinetic studies, and three clinical 
studies. The four case reports noted six women who were on contraceptive implants and 
then initiated efavirenz-based ART and experienced unintended pregnancies. In the two 
pharmacokinetic studies, the implant hormone serum concentrations were approximately 
40–60% lower in women using efavirenz-based ART versus no ART. In one of the two 
studies, three women became pregnant within the first 48 weeks of follow-up while using 
efavirenz-based ART and implants. The first clinical study from Brazil inserted 
Implanon® in 79 HIV-positive women and followed them for three years and found no 
pregnancies in the group. The second clinical study from Swaziland conducted a 
retrospective chart review of 332 Jadelle® and ART users and found that all 15 (12·4%) 
of the pregnancies were among those using efavirenz-based ART. The last clinical study 
combined data from three longitudinal studies in Africa and found that among women 
using implants, no pregnancies occurred among those on nevirapine-based ART, one 
pregnancy among those on efavirenz-based ART (6·0 pregnancies/100 w-y), and seven 
pregnancies among those on no ART (1·4 pregnancies/100 w-y).
Added value of this study
In this large cohort analysis, we found that among women using implants, those using 
efavirenz-based ART faced three times higher pregnancy rates than women using 
nevirapine-based ART. However, among women using efavirenz-based ART, those using 
other contraceptive methods, except for IUDs and permanent methods, faced up to three 
times higher pregnancy rates than women using implants.
Implications of all the available evidence
While our study supports the growing evidence that efavirenz-based ART may reduce the 
effectiveness of contraceptive implants, implants continue to remain the most effective 
and readily available form of reversible contraception in resource-limited settings, 
including in combination with efavirenz-based ART. HIV programs, providers, and 
ministries of health should continue to offer HIV-positive women the choice of selecting 
concomitant implants and efavirenz-based ART until better contraceptive and ART 
alternatives are shown to be more effective and readily available.
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Table 1
Baseline characteristics of cohort (n=94,162 observations)
Variable N (%)
Contraceptive method
 Implant 6,232 (6.6%)
  Etonogestrel implants (e.g. Implanon®) 1,512 (24.3%)
  Levonorgestrel implants (e.g. Jadelle®) 4,704 (75.5%)
 Depomedroxyprogesterone acetate (DMPA) 16,363 (17.4%)
 Combined oral contraceptives or oral contraceptive pills (COCs or OCPs) 2,495 (2.7%)
 Other more effective contraception 2,811 (3.0%)
  Intrauterine devices (IUDs) 720 (25.6%)
  Permanent methods 2,079 (74.0%)
 Less effective contraception (condoms, “natural” methods) 34,444 (36.6%)
 No contraceptive method 30,934 (32.9%)
 Missing 883 (0.94%)
Antiretroviral therapy (ART) regimen
 Nevirapine-based ART 46,132 (49.0%)
 Efavirenz-based ART 13,573 (14.4%)
 Lopinavir/ritonavir-based ART 3,649 (3.9%)
 No ART 30,494 (32.4%)
 Missing 314 (0.33%)
Age at start of observation period, median 31 (IQR 26–36)
Education level*
 None 247 (1.0%)
 Some primary school 8,943 (36.4%)
 Completed primary school 742 (3.0%)
 Some secondary school 2,912 (11.9%)
 Completed secondary school 191 (0.78%)
 Some college or university 592 (2.4%)
 Missing 10,933 (44.5%)
Marital Status*
 Married or cohabitating 10,702 (43.6%)
 Single, widowed, or divorced 6,870 (28.0%)
 Missing 6,988 (28.5%)
Number of living children (≤14 years of age), median* 2 (IQR 1–3)
Had disclosed HIV status to main sexual partner at the time of enrollment in care*
 Yes 10,298 (41.9%)
 No 7,402 (30.1%)
 Missing 6,860 (27.9%)
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Variable N (%)
Self-reported ART adherence closest to start of observation period
 “Good” 59,366 (93.2%)
 “Fair” or “Poor” 1,073 (1.7%)
 Missing 3,229 (5.1%)
Percent usage of male or female condoms used noted at each visit out of total visits during observation period, 
median
33% (IQR 0–100%)
Duration in care, since enrollment to start of observation period (in years), median 1.2 (IQR 0.25–2.7)
Total number of visits, median* 11 (IQR 5–17)
Total number of observations, median* 3 (IQR 2–5)
Total woman-time contributed to cohort (in months), median* 18 (IQR 5–30)
BMI, mean (kg/m2) 22.3 (SD 4.0)
WHO stage closest to start of observation period (within +/− one year)
 1 28,959 (30.8%)
 2 33,495 (35.6%)
 3 25,949 (27.6%)
 4 5,646 (6.0%)
 Missing 113 (0.12%)
CD4 cell count closest to start of observation period (within +/− one year), median (cells/mm3) 463 (IQR 305–657)
CD4 cell count category closest to start of observation period (within +/− one year, cells/mm3)
 0–49 2,486 (2.6%)
 50–199 9,051 (9.6%)
 200–349 17,963 (19.1%)
 350–499 21,346 (22.7%)
 ≥500 40,918 (43.5%)
 Missing 2,398 (2.6%)
Use of anti-tuberculosis drugs during observation period 3,453 (3.7%)
 Active tuberculosis treatment 2,744 (79.5%)
 Latent tuberculosis treatment 709 (20.5%)
*
These characteristics are calculated by number of women, instead of observations (n=24,560 women)
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